• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肠道微生物代谢与非酒精性脂肪性肝病

Gut Microbial Metabolism and Nonalcoholic Fatty Liver Disease.

作者信息

Sharpton Suzanne R, Yong Germaine J M, Terrault Norah A, Lynch Susan V

机构信息

Department of Medicine, Division of Gastroenterology University of California San Francisco San Francisco CA.

出版信息

Hepatol Commun. 2018 Dec 3;3(1):29-43. doi: 10.1002/hep4.1284. eCollection 2019 Jan.

DOI:10.1002/hep4.1284
PMID:30619992
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6312661/
Abstract

The gut microbiome, the multispecies community of microbes that exists in the gastrointestinal tract, encodes several orders of magnitude more functional genes than the human genome. It also plays a pivotal role in human health, in part due to metabolism of environmental, dietary, and host-derived substrates, which produce bioactive metabolites. Perturbations to the composition and associated metabolic output of the gut microbiome have been associated with a number of chronic liver diseases, including nonalcoholic fatty liver disease (NAFLD). Here, we review the rapidly evolving suite of next-generation techniques used for studying gut microbiome composition, functional gene content, and bioactive products and discuss relationships with the pathogenesis of NAFLD.

摘要

肠道微生物群是存在于胃肠道中的多种微生物群落,其编码的功能基因比人类基因组多几个数量级。它在人类健康中也起着关键作用,部分原因是环境、饮食和宿主来源的底物代谢产生生物活性代谢物。肠道微生物群的组成和相关代谢产物的扰动与多种慢性肝病有关,包括非酒精性脂肪性肝病(NAFLD)。在这里,我们综述了用于研究肠道微生物群组成、功能基因含量和生物活性产物的快速发展的新一代技术,并讨论了它们与NAFLD发病机制的关系。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b559/6312661/fc759d77aafe/HEP4-3-29-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b559/6312661/2e365ad0f1ca/HEP4-3-29-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b559/6312661/fc759d77aafe/HEP4-3-29-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b559/6312661/2e365ad0f1ca/HEP4-3-29-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b559/6312661/fc759d77aafe/HEP4-3-29-g002.jpg

相似文献

1
Gut Microbial Metabolism and Nonalcoholic Fatty Liver Disease.肠道微生物代谢与非酒精性脂肪性肝病
Hepatol Commun. 2018 Dec 3;3(1):29-43. doi: 10.1002/hep4.1284. eCollection 2019 Jan.
2
Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function.肠道微生物组在非酒精性脂肪性肝病中的新作用:从组成到功能。
Clin Gastroenterol Hepatol. 2019 Jan;17(2):296-306. doi: 10.1016/j.cgh.2018.08.065. Epub 2018 Sep 7.
3
Role of gut microbial metabolites in nonalcoholic fatty liver disease.肠道微生物代谢产物在非酒精性脂肪性肝病中的作用。
J Dig Dis. 2019 Apr;20(4):181-188. doi: 10.1111/1751-2980.12709. Epub 2019 Mar 10.
4
Gut microbiome and nonalcoholic fatty liver diseases.肠道微生物群与非酒精性脂肪性肝病
Pediatr Res. 2015 Jan;77(1-2):245-51. doi: 10.1038/pr.2014.157. Epub 2014 Oct 13.
5
Microbiome and NAFLD: potential influence of aerobic fitness and lifestyle modification.微生物群与非酒精性脂肪性肝病:有氧运动能力和生活方式改变的潜在影响
Physiol Genomics. 2017 Aug 1;49(8):385-399. doi: 10.1152/physiolgenomics.00012.2017. Epub 2017 Jun 9.
6
New insights and therapeutic implication of gut microbiota in non-alcoholic fatty liver disease and its associated liver cancer.肠道微生物群在非酒精性脂肪性肝病及其相关肝癌中的新见解和治疗意义。
Cancer Lett. 2019 Sep 10;459:186-191. doi: 10.1016/j.canlet.2019.114425. Epub 2019 Jun 8.
7
Fatty Liver Disease and Gut Microbiota: A Comprehensive Update.脂肪肝疾病与肠道微生物群:全面更新
J Clin Transl Hepatol. 2019 Mar 28;7(1):56-60. doi: 10.14218/JCTH.2018.00008. Epub 2018 Dec 28.
8
Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.肠-肝轴、营养与非酒精性脂肪性肝病。
Clin Biochem. 2015 Sep;48(13-14):923-30. doi: 10.1016/j.clinbiochem.2015.06.023. Epub 2015 Jul 4.
9
Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.调控非酒精性脂肪性肝病的肠道微生物组:益生菌、益生元、合生元和抗生素。
J Microbiol. 2018 Dec;56(12):855-867. doi: 10.1007/s12275-018-8346-2. Epub 2018 Oct 25.
10
Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Application of Metabolomics.肠道微生物群与非酒精性脂肪性肝病:代谢组学的作用机制及应用见解
Int J Mol Sci. 2016 Mar 15;17(3):300. doi: 10.3390/ijms17030300.

引用本文的文献

1
Meta-analysis of shotgun sequencing of gut microbiota in obese children with MASLD or MASH.对患有MASLD或MASH的肥胖儿童肠道微生物群进行鸟枪法测序的荟萃分析。
Gut Microbes. 2025 Dec;17(1):2508951. doi: 10.1080/19490976.2025.2508951. Epub 2025 May 21.
2
Gut Microbiota Dysbiosis: Pathogenesis, Diseases, Prevention, and Therapy.肠道微生物群失调:发病机制、疾病、预防与治疗
MedComm (2020). 2025 Apr 18;6(5):e70168. doi: 10.1002/mco2.70168. eCollection 2025 May.
3
A Literature Review of Glutathione Therapy in Ameliorating Hepatic Dysfunction in Non-Alcoholic Fatty Liver Disease.

本文引用的文献

1
Microbial enterotypes in personalized nutrition and obesity management.个性化营养和肥胖管理中的微生物肠型。
Am J Clin Nutr. 2018 Oct 1;108(4):645-651. doi: 10.1093/ajcn/nqy175.
2
Association between Cigarette Smoking Status and Composition of Gut Microbiota: Population-Based Cross-Sectional Study.吸烟状况与肠道微生物群组成之间的关联:基于人群的横断面研究。
J Clin Med. 2018 Sep 14;7(9):282. doi: 10.3390/jcm7090282.
3
Influence of Early Life, Diet, and the Environment on the Microbiome.早期生活、饮食和环境对微生物组的影响。
谷胱甘肽疗法改善非酒精性脂肪性肝病肝功能障碍的文献综述
Biomedicines. 2025 Mar 6;13(3):644. doi: 10.3390/biomedicines13030644.
4
The potential role of in liver health.在肝脏健康中的潜在作用。
Future Microbiol. 2024 Aug 12;19(12):1081-1096. doi: 10.2217/fmb-2023-0220. Epub 2024 Aug 7.
5
Double Trouble: How Microbiome Dysbiosis and Mitochondrial Dysfunction Drive Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis.双重麻烦:微生物群失调和线粒体功能障碍如何引发非酒精性脂肪性肝病和非酒精性脂肪性肝炎。
Biomedicines. 2024 Feb 29;12(3):550. doi: 10.3390/biomedicines12030550.
6
Comparing the effects of empagliflozin and liraglutide on lipid metabolism and intestinal microflora in diabetic mice.比较恩格列净和利拉鲁肽对糖尿病小鼠脂代谢和肠道菌群的影响。
PeerJ. 2024 Mar 15;12:e17055. doi: 10.7717/peerj.17055. eCollection 2024.
7
Liposome-Based Silibinin for Mitigating Nonalcoholic Fatty Liver Disease: Dual Effects via Parenteral and Intestinal Routes.基于脂质体的水飞蓟宾减轻非酒精性脂肪性肝病:通过肠外和肠道途径的双重作用
ACS Pharmacol Transl Sci. 2023 Nov 7;6(12):1909-1923. doi: 10.1021/acsptsci.3c00210. eCollection 2023 Dec 8.
8
In Vitro Screening for Probiotic Properties of and Strains in Assays Relevant for Non-Alcoholic Fatty Liver Disease Prevention.体外筛选与非酒精性脂肪性肝病预防相关的 和 菌株的益生菌特性。
Nutrients. 2023 May 18;15(10):2361. doi: 10.3390/nu15102361.
9
Therapeutic efficacy of liraglutide versus metformin in modulating the gut microbiota for treating type 2 diabetes mellitus complicated with nonalcoholic fatty liver disease.利拉鲁肽与二甲双胍在调节肠道微生物群以治疗2型糖尿病合并非酒精性脂肪性肝病方面的治疗效果。
Front Microbiol. 2023 Jan 26;14:1088187. doi: 10.3389/fmicb.2023.1088187. eCollection 2023.
10
Effects of Zhishi Daozhi Decoction on the intestinal flora of nonalcoholic fatty liver disease mice induced by a high-fat diet.止食导滞汤对高脂饮食诱导的非酒精性脂肪肝病小鼠肠道菌群的影响。
Front Cell Infect Microbiol. 2023 Jan 4;12:1005318. doi: 10.3389/fcimb.2022.1005318. eCollection 2022.
Clin Gastroenterol Hepatol. 2019 Jan;17(2):231-242. doi: 10.1016/j.cgh.2018.08.067. Epub 2018 Sep 7.
4
Post-Antibiotic Gut Mucosal Microbiome Reconstitution Is Impaired by Probiotics and Improved by Autologous FMT.抗生素后肠道黏膜微生物组重建受益生菌影响,而自体粪菌移植可改善这一过程。
Cell. 2018 Sep 6;174(6):1406-1423.e16. doi: 10.1016/j.cell.2018.08.047.
5
Personalized Gut Mucosal Colonization Resistance to Empiric Probiotics Is Associated with Unique Host and Microbiome Features.个性化肠道黏膜定植抵抗经验性益生菌与独特的宿主和微生物组特征相关。
Cell. 2018 Sep 6;174(6):1388-1405.e21. doi: 10.1016/j.cell.2018.08.041.
6
Influence of cigarette smoking on the human duodenal mucosa-associated microbiota.吸烟对人十二指肠黏膜相关微生物群的影响。
Microbiome. 2018 Aug 29;6(1):150. doi: 10.1186/s40168-018-0531-3.
7
Update on FXR Biology: Promising Therapeutic Target?FXR 生物学研究进展:有前途的治疗靶点?
Int J Mol Sci. 2018 Jul 16;19(7):2069. doi: 10.3390/ijms19072069.
8
Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women.非糖尿病肥胖女性肝脂肪变性的分子表型和宏基因组学。
Nat Med. 2018 Jul;24(7):1070-1080. doi: 10.1038/s41591-018-0061-3. Epub 2018 Jun 25.
9
The gut-liver axis and the intersection with the microbiome.肠-肝轴与微生物组的交汇。
Nat Rev Gastroenterol Hepatol. 2018 Jul;15(7):397-411. doi: 10.1038/s41575-018-0011-z.
10
Use of dietary indices to control for diet in human gut microbiota studies.使用膳食指数来控制人体肠道微生物群研究中的饮食。
Microbiome. 2018 Apr 25;6(1):77. doi: 10.1186/s40168-018-0455-y.